NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.372) was uploaded to the NHS England Website on Friday 22, August 2025.
The following changes have been introduced:
Enfortumab vedotin in combination with pembrolizumab (ENF1)
For treatment of adult patients with untreated, metastatic urothelial cancer, when platinum-based suitable where the following criteria have
Recommended for routine commissioning, receiving CDF interim funding
NA (BRE15)
NA
Moved into routine commissioning - section B of list
Fruquintinib (FRU1)
Fruquintinib for patients with either metastatic or and inoperable colorectal cancer who have received anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies anti-VEGF agents and/or anti-EGFR-based agents combination of trifluridine plus tipiracil and bevacizumab unsuitable where the following criteria have
Treatment criterion (#4) updated